From Slide #57 on the September investor Presentation;
• CytoSorb-XL is a next generation porous polymer bead technology combining
lipopolysaccharide (LPS) endotoxin removal with the robust cytokine, toxin, and
inflammatory mediator reduction achieved by CytoSorb ®
• Endotoxin is a very potent stimulator of cytokine storm, often resulting in septic shock
in serious Gram negative bacterial infections related to abdominal or urinary tract
infections, pneumonia, and hospital acquired infections
• In a head to head comparison, CytoSorb-XL matched the level of endotoxin reduction of
the leading endotoxin adsorber, Toraymyxin™ (Toray, Japan) in an in vitro plasma recirculation system
• CytoSorb-XL is expected to eliminate the need for stand alone endotoxin specific filters
by offering superior performance and removal of endotoxin and a broad range of
inflammatory mediators that drive uncontrolled deadly inflammation
• CytoSorb-XL and its novel endotoxin binding chemistry are the subject of a broad
composition of matter patent application, intended to protect the technology worldwide
for the next two decades.
CytoSorb-XL is intended to succeed CytoSorb ®
Chan said he was talking with a number of Cardiac partners. Maybe Termumo is not the primary partner they have been working with for the past two years.
Ping - management speaks of an inflection point for sales, I interpret that as at least a a substantial increase in revenues. While current receipts may not be sufficient, how do you interpret what managements description of inflection point?
During the R & R conference Chan said the company "...will break even in 2 to 3 years, if not sooner." I guess that pretty much covers it.
"Chan has NO confidence in his own technology," - you don't know that. Besides he has purchased shares on two different occasions.
I worked for for a for profit hospital corp. You might be surprised at the benefits. I doubt that available positions at the job fair will be on the acute care side - unless there would be postings in Europe.
Fresenius is a big company and it would be interesting to know how information is diseminated through the company ; conference, newsletters and etc. Since you are an ICU nurse that could be your lead to ask questions about the filters use in the European hospitals. Good luck at the job fair.
Here are the three footnotes reference in the article discussion:
47 Taniguchi T: Cytokine adsorbing columns 2010;166:134-141.
48 Peng ZY, Carter MJ, Kellum JA: Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008;36:1573-1577.
49 Quintel M: CytoSorb™ Whole Blood Cytokine Adsorption - Results of a Controlled Randomized Trial. Brussels, 32nd International Symposiumon Intensive Care and Emergency Medicine, 2012.
From the discussion in the article :
Albeit structurally different, CytoSorb and related sorbents do express excellent adsorption rates for most relevant inflammatory cytokines . Cytokine adsorbing columns have a huge surface (up to 8,500 m2) as compared with classic CRRT membranes . CytoSorb swiftly cleared 50-80% of circulating cytokines in septic animals [48,] which exceeded by far the filtering potential of HCO or high-adsorptive membranes. One clinical study randomized 43 patients to standard treatment with or without CytoSorb, 6 h daily for 7 days . CytoSorb treatment was associated with cytokine reduction and significantly lowered 28-day mortality. A major disadvantage of CytoSorb is its inability to adsorb endotoxin [48,49]. Based on current evidence, CytoSorb and other sorbents are not ready to enter clinical practice. Their potential use requires further investigation, particularly in severe inflammatory disease.
I understand what you are saying. I think the only delay was when the Refresh trial was expanded from 20 to 40 patients. Doubling the trial size implies doubling the time horizon to completion of the trial. I think the trial unfolded as planned but I believe the plan underestimated the task time for the various activities. Consequently, the actual time frame for completion is different from what is expected/planned. Perhaps management is too aggressive in projecting time frames for events to take place and simply underestimate the time frame? This is why expectations management becomes very important, unfortunately CTSO is not very good at that. If forward guidance isn't provided because of uncertainty - why should anyone expect certainty in the trial time frame.
Regardless - the company keeps making progress, the milestones are achieved (just at a pace different from what CTSO hopes), distributorships are continually added and sales are ever increasing as adoption is growing.
But your are right about about Dr. Chan's comment "...I don’t think that there was any delay." That was probably not the right choice of words as he probably could have elaborated or even asked the the question, what do you mean, before responding. And after the fact he probably realizes that too. Regardless, the evidence shows the filter works.
From the transcript, DC's comment... "CytoSorbents has not historically given financial guidance on quarterly results until the quarter has been completed. However, we currently expect a strong second half of 2016 with the achievement of numerous operating milestones. In addition we fully expect that the second half of 2015 CytoSorb sales, as well as total revenue will exceed those in the first half of 2016."
CytoSorbents Corporation (CTSO), a critical care immunotherapy company specializing in the purification of blood and bodily fluids, announced the award of $650,000 in funding through two separate Small Business Innovation Research (SBIR) grant contracts by the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue development of novel hemocompatible potassium binding polymers and substrates that can rapidly treat life-threatening hyperkalemia in critically-injured warfighters, civilian patients, and patients with impaired kidney function, such as dialysis patients.
That, may be the case. But Fresenius has 30 sales people and over a hundred hospitals, I would sum is that their marketing plan will coordinate the sales staff training and promotion efforts to start at the same time - in 30 Days someone must have sold something.
Correct-CTSO has 20MM shares of float. Subsequent quarters will be record quarters for revenue. This will be recognized a growth stock and will command a premium. I think when the market cap reaches $500MM then we should see even greater institutional interest. I expect that to be in the 4th quarter. In the mentire try to add to your position on these pull backs.
It is not obvious but I listened to replay by finding the PR announcing that CTSO is going to present at the CF event. That PR was sent around the 6th. Open that pr and it should take you to the web cast.